dihydroergotamine has been researched along with lopinavir in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
| Alves, M; Guidet, B; Janneau-Magrino, L; Legendre, N; Pateron, D; Yordanov, Y | 1 |
3 other study(ies) available for dihydroergotamine and lopinavir
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |
Human immunodeficiency virus post-exposure prophylaxis: primum non nocere.
Topics: Adult; Antiviral Agents; Bipolar Disorder; Cytochrome P-450 CYP3A Inhibitors; Dihydroergotamine; Drug Synergism; Drug Therapy, Combination; Ergotism; Female; HIV Infections; Humans; Hypotension, Orthostatic; Lamivudine; Lopinavir; Post-Exposure Prophylaxis; Ritonavir; Vasoconstrictor Agents; Zidovudine | 2015 |